Home » Stocks » PVCT

Provectus Biopharmaceuticals, Inc. (PVCT)

Stock Price: $0.0730 USD -0.0020 (-2.67%)
Updated Feb 23, 2021 3:48 PM EST - Market closed
Market Cap 29.27M
Revenue (ttm) n/a
Net Income (ttm) -6.56M
Shares Out 393.50M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 23
Last Price $0.0730
Previous Close $0.0750
Change ($) -0.0020
Change (%) -2.67%
Day's Open 0.0749
Day's Range 0.0657 - 0.0749
Day's Volume 436,448
52-Week Range 0.03 - 0.1


GlobeNewsWire - 1 month ago

KNOXVILLE, TN, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) has released a manuscript preprint describing how investiga...

About PVCT

Provectus Biopharmaceuticals, a clinical-stage biotechnology company, engages in developing drugs based on halogenated xanthenes for oncology, hematology, and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase Ib/II study for metastatic melanoma; Phase I study for hepatocellular carcinoma and other solid tumors metastatic to the liver; and non-clinical assessment of pediatric cancer tumor cell. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis... [Read more...]

Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements